• 1
    Mettlin C, Murphy GP, Rosenthal DS, Menck HR. The National Cancer Data Base report on prostate carcinoma after the peak in incidence rates in the US. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1998; 83: 167984
  • 2
    Iversen P, Melezinek I, Schmidt A. Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function. BJU Int 2001; 87: 4756
  • 3
    Stone P, Hardy J, Huddart R, A'Hern R, Richards M. Fatigue in patients receiving hormone therapy. Eur J Cancer 2000; 36: 113441
  • 4
    Furr BJA, Kaisary AV. Treatment: hormonal manipulation: Antiandrogens. In KaisaryAV Murphy GP, DenisL, GriffithsK eds Textbook of Prostate Cancer: Pathology, Diagnosis and Treatment. London: Martin Dunitz, 1999: 277 – 90
  • 5
    Moffat LE. Comparison of Zoladex, diethylstilboestrol and cyproterone acetate treatment in advanced prostate cancer. Eur Urol 1990; 18 (Suppl. 3): 267
  • 6
    Thorpe SC, Azmatullah S, Fellows GJ, Gingell JC, O'Boyle PJ. A prospective, randomised study to compare goserelin acetate (Zoladex®) versus cyproterone acetate (Cyprostat®) versus a combination of the two in the treatment of metastatic prostatic carcinoma. Eur Urol 1996; 29: 4754
  • 7
    Boccon-Gibod L, Fournier G, Bottet P et al. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. Eur Urol 1997; 32: 3915
  • 8
    Pavone-Macaluso M. Flutamide monotherapy versus combined androgen blockade in advanced prostate cancer. Interim report of an Italian multicentre, randomised study. SIU 23rd Congress 1994: A354
  • 9
    Tyrrell CJ, Kaisary AV, Iversen P et al. A randomised comparison of ‘Casodex’ (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 1998; 33: 44756
  • 10
    Iversen P, Tyrrell CJ, Kaisary AV et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol 2000; 164: 157982
  • 11
    Fourcade RO, Chatelain C, Poterre M. An open multicentre randomised study to compare the effect and safety of ‘Casodex’ (bicalutamide) 150 mg monotherapy with castration plus nilutamide in metastatic prostate cancer. Eur Urol 1998; 33 (Suppl. 1): 88 (A349)
  • 12
    Boccardo F, Rubagotti A, Barichello M et al. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients. Results of an Italian prostate cancer project (PONCAP) study. J Clin Oncol 1999; 17: 202738
  • 13
    Mahler C, Verhelst J, Denis L. Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer. Clin Pharmacokinet 1998; 34: 40517
  • 14
    Decensi AU, Boccardo F, Guarneri D et al. Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. J Urol 1991; 146: 37781
  • 15
    Dole EJ, Holdsworth MT. Nilutamide: an antiandrogen for the treatment of prostate cancer. Ann Pharmacother 1997; 31: 6575
  • 16
    Dudov A, Todorov D. Goserelin versus flutamide in previously untreated advanced prostate cancer. Can J Infect Dis 1995; 6: 396 (A3034)
  • 17
    Jacobo E, Schmidt JD, Weinstein SH, Flocks RH. Comparison of flutamide (SCH-13521) and diethylstilbestrol in untreated advanced prostatic cancer. Urology 1976; 8: 2313
  • 18
    Lund F, Rasmussen F. Flutamide versus stilboestrol in the management of advanced prostatic cancer. A controlled prospective study. Br J Urol 1988; 61: 1402
  • 19
    Chang A, Yeap B, Davis T et al. Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol. J Clin Oncol 1996; 14: 22507
  • 20
    Schröder FH, Collette L, De Reijke TM, Whelan P. Prostate cancer treated by anti-androgens: is sexual function preserved? EORTC Genitourinary Group. European Organization for Research and Treatment of Cancer. Br J Cancer 2000; 82: 28390
  • 21
    Kolvenbag GJ, Nash A. Bicalutamide dosages used in the treatment of prostate cancer. Prostate 1999; 39: 4753
  • 22
    Tyrrell CJ, Denis L, Newling D, Soloway M, Channer K, Cockshott ID. Casodex 10–200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Casodex Study Group. Eur Urol 1998; 33: 3953
  • 23
    Iversen P, Tyrrell CJ, Kaisary AV et al. Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years. Urology 1998; 51: 38996
  • 24
    Kaisary AV, Iversen P, Tyrrell CJ, Carroll K, Morris T. Is there a role for antiandrogen monotherapy in patients with metastatic prostate cancer? Prost Cancer Prost Dis 2001; 4: 196203
  • 25
    Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000; 63: 1816
  • 26
    Tyrrell CJ, Blake GM, Iversen P et al. ‘Casodex’ may preserve bone mineral density of patients with advanced prostate cancer. BJU Int 2000; 86 (Suppl. 3): MP6.1.09
  • 27
    Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer. an overview of the randomised trials. Lancet 1998; 351: 145167
  • 28
    See WA, Wirth MP, McLeod DG et al. Bicalutamide as immediate therapy either alone or as adjuvant to standard care in patients with localized or locally advanced prostate cancer: first analysis of the Early Prostate Cancer Program. J Urol 2002; 168: 42935
  • 29
    Migliari R, Muscas G, Murru M, Verdacchi T, De Benedetto G, De Angelis M. Antiandrogens: a summary review of pharmacodynamic properties and tolerability in prostate cancer therapy. Arch Ital Urol Androl 1999; 71: 293302
  • 30
    Paisey RB, Kadow C, Bolton C, Hartog M, Gingell JC. Effects of cyproterone acetate and a long-acting LHRH analogue on serum lipoproteins in patients with carcinoma of the prostate. J R Soc Med 1986; 79: 2101
  • 31
    McLeod DG. Tolerability of nonsteroidal antiandrogens in the treatment of advanced prostate cancer. Oncologist 1997; 2: 1827
  • 32
    McLeod DG, Iversen P. Gynecomastia in patients with prostate cancer. a review of treatment options. Urology 2000; 56: 71320
  • 33
    Oosterlinck W, Casselman J, Mattelaer J, Van Velthoven R, Kurjatkin O, Schulman C. Tolerability and safety of flutamide in monotherapy, with orchiectomy or with LHRH-a in advanced prostate cancer patients. A Belgian multicenter study of 905 patients. Eur Urol 1996; 30: 45863
  • 34
    Tyrrell C, Morris T, Carroll K. Prophylactic breast irradiation significantly reduces the incidence of bicalutamide-induced gynaecomastia. Eur Urol 2002; 41 (Suppl. 1): 136 (A536)
  • 35
    Kaisary AV. Compliance with hormonal treatment for prostate cancer. Br J Hosp Med 1996; 55: 35966
  • 36
    Cockshott ID, Cooper KJ, Sweetmore DS, Blacklock NJ, Denis L. The pharmacokinetics of Casodex in prostate cancer patients after single and during multiple dosing. Eur Urol 1990; 18 (Suppl. 3): 107